ARS Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $420.09M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 9, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $33.70M | $-0.63 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | $22.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | Before market open | $28.10M | $0.42 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | Before market open | $32.50M | $-0.52 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-0.46 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | Before market open | $86.60M | $0.48 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $2.10M | $-0.20 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| aggregate SG&A and R&D expenses | second half of 2026 | $114.00M to $126.00M | New |
| stock-based compensation expense | second half of 2026 | $14.00M to $16.00M | Lowered |
| total cash-based SG&A and R&D expensesnon-GAAP | second half of 2026 | $100.00M to $110.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements ARS Pharmaceuticals filed with the SEC
ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
May 2026 Corporate Presentation neffy – the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy ® (epinephrine nasal spray) Commercialization
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
March 2026 Corporate Presentation neffy – the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy ® (epinephrine nasal spray)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
November 2025 Corporate Presentation neffy – the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy ® (epinephrine nasal spray)
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 2025 neffy – the transformative needle-free solution for severe allergic reactions Exhibit 99.2 NASDAQ: SPRY
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)
Results of operations · EX-99.1 to Form 8-K
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
43rd Annual J.P. Morgan Healthcare
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
the design and potential benefits of neffy, including the likelihood allergy patients and caregivers will choose to carry and dose neffy compared to needle-bearing options; ARS Pharma’s expected competitive position; the potential market,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARS Corporate Presentation June 28,
Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Corporate Presentation June 28,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ARS Corporate Presentation Q2 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements Statements in this presentation that are not
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
ARS Corporate Presentation Q4 2023
Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates
Results of operations · EX-99.1 to Form 8-K
SOLUTION for Type I Allergic Reactions Q2 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Drug name: ARS-1 (intranasal epinephrine)
Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
Allergic Reactions Q1 2023 1
Regulation FD disclosure · EX-99.1 to Form 8-K
SOLUTION for Type I Allergic Reactions Q1 2023 Exhibit 99.1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
SOLUTION for Type I Allergic Reactions December 6, 2022 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
Material agreement · Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Merger Announcement July 21, 2022
Material agreement · Exit or restructuring costs · Executive or director change · Other events · EX-99.2 to Form 8-K
On July 21, 2022, Silverback Therapeutics, Inc. (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) hosted an investor conference
Material agreement · Exit or restructuring costs · Executive or director change · Other events · EX-99.3 to Form 8-K
Silverback Therapeutics Reports First Quarter 2022 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021
Results of operations · EX-99.1 to Form 8-K
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K